Our focus is on neurochemicals acting on the peripheral and central nervous system

We are enthusiastic about neurochemicals acting as agonists or antagonists on G-protein coupled receptors located in the peripheral and central nervous system. Our goal is to address the clinical needs to diagnose and treat the neurological pathologies at the origin of the disease; thus, avoiding a merely systematic treatment and rather stopping or delaying disease progression.

The chemical structure of small molecules is the key for successful drug design and development for both imaging probes and therapeutics. The combined, interdisciplinary knowledge of medicinal chemists, pharmacists and physicians allows drug adjustment and pave the way towards the application of our substances as tools for image-guided therapy.

The bottleneck of the drug development process is the preclinical screening of a compound library, as we still lack substantial methods for a fast and reliable biological assessment. We developed a complex dynamic 3D-cell culture method, which mimics the tissue situation and has the potential to fasten the screening process. Moreover, it conforms with the 3Rs (reduce, replace, refine) rule in animal ethics and will contribute to reduce the number of animals needed in drug testing.

Our main interests lie in

  • Inventive drug and tracer development of neurochemicals
  • Innovative drug screening methods
  • Interdisciplinary approaches close to medical application

EANM 2021 Plenary Lecture - Isotopes Past and Future

Missed the EANM 2021 plenary lecture on the availability of medicinal radioisotopes.

You can still watch it here.

News and announcements

17.08.2022
 

Nina finishes her excellent master thesis with the title „Fast gradient HPLC method to determine lipophilicity and binding to human serum albumin of mAChR ligands“.

We wish her all the best for her future carreer.

10.07.2022
 

Congratulations to Karsten, who published his 1. first-author publication in NucMedBiol on the radiochemical optimization of [18F]Fluorodopamine synthesis.

04.06.2022
 

During ERASMUS+ program, we were visiting our cooperation partners in Kaunas, Lithuania. We are grateful to have this partnership with Prof. Egle Arbaciauskiene, an expert in organic and medicinal chemistry.

19.05.2022
 

Building on our recent successes with arecaidine-derived ligands targeting M1, herein we report the synthesis of a related series of 11 hydroxylated arecaidine esters. Overall, this study greatly expanded our understanding of this recurring scaffolds’ structure–activity relationship and will guide the development towards highly selective mAChRs ligands.

24.03.2022
 

Micro- and nanoplastics (MNPs) are recognized as emerging contaminants, especially in food, with unknown health significance. We discuss new insights into analytical and molecular modeling tools to help us better understand the local deposition and uptake of MNPs that might drive carcinogenic signaling. We present bioethical insights to basically reconsider the “culture of consumerism.”

 

science.orf.at/stories/3212162/

16.03.2022
 

Congratulation to the oral presentation of our recently published paper on DUAL-tracer application by Chrysoula Vraka at the EMIM2022 in Greece, Thessaloniki.